Section 01
What it's used for
Sleep Effects Were Weak in Trials
Small human trials tested DSIP for insomnia, including a 16-patient study. A 1987 trial found no change in deep or REM sleep; a 1992 trial found no improvement in sleep quality versus placebo. Effects were called weak.
▸Clinical wording
DSIP has been tested in small human trials in chronic insomniacs, including a crossover polysomnography study and a 16-patient double-blind trial. These studies found only modest effects: the 1987 trial reported that slow-wave sleep and REM sleep were not modified, and the 1992 trial found no change in subjective sleep quality versus placebo. Both trials concluded the effect was weak and not likely to be of major therapeutic benefit, so claims that DSIP is particularly effective for normalizing disrupted sleep architecture are not supported.
Stress Hormones: Animal Data Only
In rats, DSIP changed stress-hormone levels under lab stress. But a 1995 human trial found it did not affect ACTH or cortisol in people, and calming effects were seen only in a mouse study — no human anxiety trial was found.
▸Clinical wording
Evidence for DSIP's effects on stress hormones comes mainly from rat studies showing changes in corticosterone under CRF challenge or emotional-stress protocols. The one human hormone study identified, a 1995 infusion trial, found that DSIP did not affect ACTH or cortisol secretion in people, contradicting claims that it normalizes cortisol rhythms in humans. No human study of reduced anxiety scores in chronically stressed subjects was found; an anxiolytic effect has only been reported in a mouse elevated-plus-maze study, so use of DSIP for chronic stress and burnout is not supported by human clinical evidence.
Opioid and Alcohol Withdrawal
In human clinical studies, DSIP reduced withdrawal symptoms from opioids and alcohol — including anxiety, insomnia, autonomic symptoms, and cravings. Researchers link this to rebalancing the body's opioid and GABA signaling systems.
▸Clinical wording
Clinical studies demonstrate DSIP reduces withdrawal symptoms from opioids and alcohol, including anxiety, insomnia, autonomic dysfunction, and craving. The mechanism involves normalization of endogenous opioid and GABAergic systems disrupted by substance dependence.
Chronic Pain Conditions
Is being studied for chronic pain, including migraine, fibromyalgia, and nerve pain. Researchers are looking at both its direct pain-relieving effects and its influence on the body's own opioid signaling system.
▸Clinical wording
DSIP's opioid-modulating and direct analgesic properties have been studied for chronic pain conditions, including headache/migraine, fibromyalgia, and neuropathic pain.
Jet Lag and Shift Work
Is being studied for circadian rhythm problems such as jet lag, shift-work sleep disorder, and age-related disruption of the body clock. Researchers are looking at whether it helps resynchronize sleep-wake timing.
▸Clinical wording
DSIP research addresses jet lag, shift work disorder, and age-related circadian disruption. Its chronobiotic properties help re-synchronize disrupted sleep-wake rhythms.
Neurodegeneration Research
Is being studied in neurodegenerative disease research for its antioxidant and nerve-protecting properties, in conditions where oxidative cell damage and disrupted sleep are both common, prominent features of the disease process.
▸Clinical wording
DSIP's antioxidant and neuroprotective properties are researched in the context of neurodegenerative diseases, where oxidative stress and sleep disruption are prominent features.
Section 02
Mechanism of Action
Pushing sleep toward its deepest stage
- DSIP is described as promoting slow-wave deep sleep by acting on sleep-regulating brain regions.
- It is said to strengthen calming signalling in the main sleep-triggering nucleus of the brain.
- It is described as quieting the wake-promoting nerve cells of the lateral hypothalamus.
- The stated net effect is a shift in sleep architecture toward more deep sleep.
▸Clinical wording
Delta Wave Sleep Promotion
DSIP promotes slow-wave (delta) sleep by modulating neuronal activity in sleep-regulating brain regions. It enhances GABAergic signaling in the ventrolateral preoptic area (VLPO) — the primary sleep-active nucleus — while suppressing wake-promoting orexin/hypocretin neurons in the lateral hypothalamus. The net effect is a shift in sleep architecture toward increased stage 3/4 deep sleep.
Steadying the stress hormone system
- DSIP is described as a stress-protective peptide acting on the body's stress hormone axis.
- It is said to reduce excessive cortisol and the pituitary stress signal (ACTH) during chronic stress.
- Appropriate short-term stress responses are described as preserved rather than blunted.
- This two-way adjustment is what distinguishes adaptogens from simple stress suppressors.
▸Clinical wording
Stress Response Modulation (Adaptogenic)
DSIP acts as a stress-protective (adaptogenic) peptide. It normalizes the HPA axis response to stress — reducing excessive cortisol and ACTH release during chronic stress while preserving appropriate acute stress responses. This bidirectional modulation is characteristic of adaptogens rather than simple stress suppressors.
Nudging hormones back toward balance
- DSIP is described as adjusting pituitary hormone release in a normalising direction.
- It is said to stimulate release of luteinising hormone and growth hormone.
- It is described as suppressing excess of a growth hormone brake and normalising daily cortisol rhythm.
- These effects are described as context-dependent, correcting deviations rather than forcing one direction.
▸Clinical wording
Endocrine Normalization
DSIP modulates pituitary hormone secretion in a normalizing manner. It stimulates LH and GH release, suppresses excess somatostatin, and normalizes cortisol rhythms. These effects are context-dependent — DSIP tends to correct deviations from homeostasis rather than forcing hormonal changes in a single direction.
Touching the body's own painkiller system
- DSIP is described as altering the body's own opioid signalling.
- It is said to raise a natural painkiller peptide (met-enkephalin) in brain tissue.
- Sensitivity of opioid receptors is described as modulated as well.
- This is offered as the basis for reported pain relief and reduced withdrawal symptoms.
▸Clinical wording
Opioid System Interaction
DSIP modulates endogenous opioid signaling — enhancing met-enkephalin levels in brain tissue and modulating opioid receptor sensitivity. This contributes to its analgesic properties and its ability to reduce withdrawal symptoms from opioids and alcohol.
Mopping up reactive oxygen molecules
- DSIP is described as neutralising reactive oxygen molecules both directly and indirectly.
- It is said to raise expression of the body's own antioxidant enzymes.
- This is offered as a possible contributor to its protective effects rather than a demonstrated one.
▸Clinical wording
Antioxidant Activity
DSIP exhibits direct and indirect antioxidant properties, scavenging reactive oxygen species and enhancing endogenous antioxidant enzyme expression (SOD, catalase). This may contribute to its neuroprotective and stress-protective effects.
Section 03
Biological Pathways
- GABAergic Sleep CircuitryDSIP enhances GABA-A receptor-mediated inhibition in the VLPO and median preoptic nucleus, promoting sleep-active neuron firing, while inhibiting wake-promoting histamine and norepinephrine circuits.
- HPA Axis ModulationDSIP normalizes hypothalamic CRH release, reducing excessive CRH/ACTH/cortisol output under stress while preserving normal circadian cortisol patterns via glucocorticoid receptor sensitivity.
- Enkephalin/Opioid PathwayDSIP increases met-enkephalin concentrations in the brain, enhancing δ-opioid receptor signaling, mediating analgesic effects and contributing to anxiolysis and stress resilience.
- Circadian Clock RegulationDSIP influences core clock gene expression and melatonin synthesis, helping synchronize circadian rhythms, which may underlie its ability to normalize disturbed sleep-wake patterns.
Section 04
Dosage Information
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu| Route / system | Context | Range studied | Limitation |
|---|---|---|---|
| Intravenous — 1970s–80s sleep studies | Small European trials in chronic insomnia | About 21 µg/kg (25 nmol/kg) by slow infusion — 1.5–1.9 mg for a 70–90 kg adult, on four to seven nights in a row | Six to sixteen people per trial. In the 1987 one the authors called the sleep gain of little clinical significance; nothing larger has run since. |
| Intravenous — withdrawal treatment | Open series in alcohol and opiate withdrawal, 1984 | The same 21 µg/kg (25 nmol/kg) — 1.5–1.9 mg for a 70–90 kg adult — over about two weeks in 107 inpatients (47 alcohol, 60 opiate) | No control group and no blinding: the treating doctors scored the results, all from one research group. Forty years on, nobody has repeated it. |
| Subcutaneous — self-administration | Circulating practice, no published human study | 100–300 µg once in the evening — about 1.1–4.3 µg/kg for a 70–90 kg adult, a fifth to a twentieth of the 21 µg/kg the trials infused | Nothing ties this number to the trial data: a different route, nothing measured under the skin in people, and no sign it reaches the brain. |
Results
Syringe Fill Level (100u syringe)
Set positive values for: Recommended dose per kg.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Section 05
Protocols
- Protocol 01
DSIP Sleep Enhancement Protocol
Delta sleep-inducing peptide for improved sleep quality, recovery, and stress reduction.
- Focus
- Sport & Performance
- Level
- Beginner
- Duration
- 8–12 weeks
Section 06
Stability & Storage
Lyophilised powder
Supplied as a white lyophilised powder; kept at -20 °C for long-term storage (12-18 months) or at 2-8 °C for up to 3 months. Its linear structure makes it more fragile than many peptides and prone to aminopeptidase degradation, and the tryptophan residue is light-sensitive, so it is protected from light. It is reconstituted with bacteriostatic water.
After reconstitution
Store the reconstituted solution at 2-8 °C and use it within 14-21 days. Acidic conditions (pH below 4) can cause aspartate isomerisation, so the solution is kept close to neutral pH; various approaches such as phosphorylated derivatives or encapsulation have been explored to improve its stability.
Section 07
Side Effects & Precautions
Clinical studies report minimal adverse effects with DSIP at therapeutic doses.
When drowsiness carries into the morning
Drowsiness is the expected, generally desired effect, but it can persist into the following morning if the dose is taken too close to the intended wake time.
DSIP is typically administered 30-60 minutes before the desired onset of sleep.
Short duration of action
The short half-life (~7-8 minutes) limits the duration of effect.
Sleep-maintaining effects may not persist through the full night, so some people wake earlier than desired.
Mild reported effects
- Occasional headache during initial use, typically resolving with continued administration.
- Mild redness or discomfort at subcutaneous injection sites.
Limited long-term data
Comprehensive long-term safety studies are not available; most clinical data comes from short-term use (weeks to months).
Some reports suggest diminishing effects with prolonged daily use, though this is not consistently documented in clinical literature.
Section 08
Regulatory Status
Its regulatory trajectory points toward continued restriction, not the loosening that six comparable peptides just received.
FDA / United States
Not approved
Emideltide (DSIP) was not on the 503A Bulks List as of 5 August 2026, and section 503A lets a pharmacy compound from a bulk substance only when it carries a USP/NF monograph, is a component of an approved drug or appears on that list — so no lawful compounding route is open. In 2023 the FDA had assigned it to Category 2 of the interim bulk-substances list, among compounds it judged to carry significant safety risk.
FDA review
A committee voted against inclusion
On 24 July 2026 the Pharmacy Compounding Advisory Committee voted 6 to 7 not to add Emideltide (DSIP) to the 503A Bulks List — the only rejection among the seven peptides reviewed that session. The panel found the evidence insufficient for the nominated subcutaneous route; only inconclusive intravenous data existed.
Historical clinical use
Used off-label in a few countries
Physicians in Switzerland, Germany, and Russia have used DSIP for insomnia and sleep disorders outside any formal marketing authorisation; none of these countries lists it as an approved medicine, and the practice does not extend to the United States.
WADA
Not on the prohibited list
DSIP does not appear on the WADA Prohibited List and is not classified as a controlled substance in the United States or the European Union, so its regulatory friction currently comes from drug law, not anti-doping rules.
A single committee's rejection is not a final ruling — the FDA changes the 503A Bulks List only through separate rulemaking, and no peptide from that session had been added as of this check. Regulatory status differs between jurisdictions and changes over time; check the current documents of your own regulator before relying on any of this.
We cover the 23–24 July 2026 vote of the FDA's Pharmacy Compounding Advisory Committee (PCAC) separately, in «The 2026 PCAC Peptide Vote» (/en/articles/fda-pcac-2026-peptides). The committee reviewed DSIP under its international nonproprietary name, Emideltide, and on 24 July voted against adding it to the 503A Bulks List — 6 votes to 7, the only rejection among the seven peptides reviewed; here the committee agreed with the FDA's own reviewers, who had recommended against listing all seven. A rejection by the committee is still a recommendation rather than a final ruling: the list changes only through formal rulemaking, which usually takes 8–12 months, and even inclusion would not make a substance an approved medicine.
Section 09
Research Studies
- [1]Characterization of a delta-electroencephalogram (-sleep)-inducing peptideSchoenenberger GA, Monnier M · Proceedings of the National Academy of Sciences · 1977
- [2]Delta-sleep-inducing peptide (DSIP): a reviewGraf MV, Kastin AJ · Neuroscience & Biobehavioral Reviews · 1984
- [3]Delta sleep-inducing peptide (DSIP): a still unresolved riddleKovalzon VM, Strekalova TV · Journal of Neurochemistry · 2006
- [4]Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the ratIyer KS, Marks GA, Kastin AJ, McCann SM · Proceedings of the National Academy of Sciences · 1988
- [5]Effects of delta sleep-inducing peptide on pre- and postsynaptic glutamate and postsynaptic GABA receptors in neurons of the cortex, hippocampus, and cerebellum in ratsGrigor'ev VV, Ivanova TA, Kustova EA, Petrova LN, Serkova TP, Bachurin SO · Bulletin of Experimental Biology and Medicine · 2006
- [6]Delta sleep inducing peptide inhibits somatostatin release via a dopaminergic mechanismIyer KS, McCann SM · Neuroendocrinology · 1987
- [7]Delta sleep inducing peptide (DSIP) stimulates the release of LH but not FSH via a hypothalamic site of action in the ratIyer KS, McCann SM · Brain Research Bulletin · 1987
- [8]Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacsSchneider-Helmert D · European Neurology · 1986
- [9]Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxiaKhvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II · Peptides · 2003
- [10]Effect of delta sleep-inducing peptide on the expression of antioxidant enzyme genes in the brain and blood of rats during physiological agingKutilin DS, Bondarenko TI, Kornienko IV, Mikhaleva II · Bulletin of Experimental Biology and Medicine · 2014
Section 10
Frequently Asked Questions
The direct sleep evidence is weaker than the name suggests. A 1987 crossover polysomnography study in chronic insomniacs found that slow-wave and REM sleep were not modified, and a 1992 double-blind trial in 16 patients found no change in subjective sleep quality versus placebo; both concluded any effect was weak and unlikely to be of major therapeutic benefit. No larger or more recent human sleep trial has been run since.
The trials that exist used roughly 21 µg/kg by slow intravenous infusion, about 1.5 to 1.9 mg for a 70-90 kg adult. Circulating self-administration practice uses 100 to 300 µg once in the evening under the skin — a fifth to a twentieth of the trial dose, by a different route, with nothing measured about whether a subcutaneous shot reaches the brain at all.
Human data contradict that claim. The one human hormone study identified, a 1995 infusion trial, found that DSIP did not affect ACTH or cortisol secretion in people. The corticosterone changes and anxiety-reducing effects often cited for DSIP come from rat stress protocols and a mouse elevated-plus-maze study, not from human trials.
An open, uncontrolled 1984 series gave DSIP intravenously to 107 inpatients — 47 with alcohol withdrawal, 60 with opiate withdrawal — and reported reduced withdrawal symptoms. There was no control group and no blinding, the treating physicians scored the outcomes themselves, and no one has repeated the study in the four decades since.
Clinical studies describe a generally favourable safety profile at the doses tested. Drowsiness is expected and can carry into the next morning if dosing sits too close to wake time; occasional mild headache and injection-site reactions are also reported. DSIP's short half-life, around 7 to 8 minutes, means any sleep-maintaining effect may not last through a full night, and long-term safety data beyond weeks to months of use are not available.
DSIP has no FDA approval and is classified as an investigational research compound in the United States and most Western countries, though it has been used clinically for insomnia in some European countries and in Russia. It is not on the WADA prohibited list and is not a controlled substance.
The lyophilised powder is kept at -20°C for 12 to 18 months, or at 2-8°C for up to 3 months, and protected from light because its tryptophan residue is light-sensitive. Once reconstituted, the solution is stored at 2-8°C and used within 14 to 21 days, kept near neutral pH since acidic conditions can degrade the peptide.